Effects of the SGLT2 inhibitor on erythropoiesis and iron homeostasis in patients with type 2 diabetes and chronic kidney disease - Effects of the SGLT2 inhibitor on erythropoiesis and iron homeostasis in patients with type 2 diabetes and chronic kidney disease

aka Kinen Clinic0 个研究点目标入组 14 人开始时间: 2021年3月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Type 1 diabetes 2.Patients with severe ketosis, diabetic coma or pre-coma, severe infection, perioperative, or severe trauma 3.Patients with severe renal dysfunction or treated with hemodialysis for end-stage renal disease 4.History of acute coronary syndrome, cerebrovascular disease, myocarditis, contractile pericarditis, or severe valvular disease within 12 weeks before consent 5.NYHA cardiac function classification of IV 6.BMI <18.5 kg/m2 7.Pregnant, breast-feeding, or possibly pregnant women 8.Diagnosed or suspected malignant tumors (patients who do not have a treatment history of anticancer therapy within 1 year before consent, and have no plan to do so will not be excluded) 9.Patients in the study is judged by the investigator or sub-investigator as inappropriate for any other reason

发起方

aka Kinen Clinic